Novel Canine Coronavirus Isolated from a Hospitalized Pneumonia Patient, East Malaysia

Anastasia N. Vlasova (PhD), Annika Diaz, Debasu Damtie (MS), Leshan Xiu (MS), Teck-Hock Toh (MD), Jeffrey Soon-Yit Lee (MD), Linda J. Saif (PhD), and Gregory C. Gray (MD)

1Food Animal Health Research Program, Ohio Agricultural Research and Development Center, College of Food, Agricultural and Environmental Sciences, Department of Veterinary Preventive Medicine, The Ohio State University, Wooster, Ohio, USA.

2Department of Immunology and Molecular Biology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia

3The Ohio State University Global One Health LLC, Eastern Africa Regional Office, Addis Ababa, Ethiopia

4Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, USA

5Duke Global Health Institute, Duke University, Durham, North Carolina, USA

6NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

7Clinical Research Center, Sibu Hospital, Ministry of Health Malaysia, Sibu, Sarawak, Malaysia

8Faculty of Medicine, SEGi University, Kota Damansara, Selangor, Malaysia

9Global Health Research Center, Duke Kunshan University, Kunshan, China

10Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
These two authors contributed equally.

Corresponding author:
Gregory C. Gray, MD, MPH, FIDSA
Professor, Division of Infectious Diseases
DUMC Box 102359
Duke University
Durham, NC 27710
gregory.gray@duke.edu
+1 (919) 684-1032

**Key points:** This is the first complete genome characterization of a novel canine-feline recombinant alphacoronavirus isolated from a child with pneumonia. Similar to severe acute respiratory syndrome coronavirus, this novel virus possesses some unique genetic features suggestive of recent zoonotic transmission.
ABSTRACT

BACKGROUND During the validation of a highly sensitive pan-species coronavirus (CoV) semi-nested RT-PCR assay, we found canine CoV (CCoV) RNA in nasopharyngeal swabs from eight (2.5%) of 301 patients hospitalized with pneumonia during 2017-18 in Sarawak, Malaysia. Most patients were children living in rural areas with frequent exposure to domesticated animals and wildlife.

METHODS Specimens were further studied with universal and species-specific CoV and CCoV one-step RT-PCR assays, and viral isolation was performed in A72 canine cells. Complete genome sequencing was conducted using Sanger method.

RESULTS Two of eight specimens contained sufficient amounts of CCoVs as confirmed by less-sensitive single-step RT-PCR assays, and one specimen demonstrated cytopathic effects (CPE) in A72 cells. Complete genome sequencing of the virus causing CPE identified it as a novel canine-feline recombinant alphacoronavirus (genotype II) that we named CCoV-HuPn-2018. Most of CCoV-HuPn-2018 genome is more closely related to a CCoV TN-449, while its S gene shared significantly higher sequence identity with CCoV-UCD-1 (S1 domain) and a feline CoV WSU 79-1683 (S2 domain). CCoV-HuPn-2018 is unique for a 36 nt (12-aa) deletion in the N protein and the presence of full-length and truncated 7b non-structural protein which may have clinical relevance.

CONCLUSIONS This is the first report of a novel canine-feline recombinant alphacoronavirus isolated from a human pneumonia patient. If confirmed as a pathogen, it may represent the eighth unique coronavirus known to cause disease in humans. Our findings underscore the public health threat of animal CoVs and a need to conduct better surveillance for them.

Keywords: canine coronavirus; novel alphacoronavirus; pneumonia; zoonotic disease; East Malaysia
Human coronaviruses (HCoVs) associated with common colds (HCoV-229E and HCoV-OC43) were initially identified in the mid-sixties, and two more, HCoV-NL63 and HCoV-HKU1, were described in 2004 and 2005, respectively [1-3]. The emergence of severe acute respiratory syndrome (SARS) coronavirus (CoV) in 2002-2003 and Middle East respiratory syndrome (MERS)-CoV in 2012 has demonstrated that CoVs can cause severe-to-fatal disease [4]. Evidence suggests that bats are likely to be the original source of SARS-CoV and MERS-CoV [5, 6]. The most recent and notable CoV-related threat is represented by the COVID-19 pandemic caused by SARS-CoV-2 [7]. While the origin of SARS-CoV-2 is still debated [8], it is thought to have emerged via a spillover event originating at a Chinese wet market. Thus, zoonotic CoVs pose a major threat to human health with different animals serving as natural reservoirs/intermediate hosts to CoVs transmittable to humans [9, 10]. However, the potential threat represented by cats and dogs or their CoVs has been sparsely studied.

Different genotypes (I,II) of canine CoVs (CCoVs) of Alphacoronavirus 1 species cause moderate-to-severe enteric disease in dogs [11]. CCoV-II circulation has been confirmed in dogs since 1971, while CCoV-I was discovered about 3 decades later [12, 13]. TGEV, CCoV-II and feline CoV (FCoV)-II have reportedly originated from CCoV-I and FCoV-I through gene loss and recombination [14]. Similar to FCoVs, CCoV-I strains do not grow or grow poorly in cell culture and their cellular receptor is unknown, while CCoV-II strains grow readily in culture utilizing aminopeptidase N (APN) as a cellular receptor [15]. This emphasizes the complex evolution of CCoVs/Alphacoronavirus 1 species and their ability to infect different hosts inducing variable clinical disease. It has been demonstrated recently that another CoV, porcine deltacoronavirus, utilizing APN as a cellular receptor can infect cells of an unusually broad species origin, including human and chicken [16].

Our recent studies documenting CCoV in human pneumonia patients in Sarawak [17] and FCoV-like CoVs in human patients with acute respiratory symptoms in Arkansas [18] represent the only
evidence that *Alphacoronavirus 1* species may infect and be associated with a clinical disease in humans. Here we report isolation, complete genome sequencing and molecular analysis of a CCoV virus from one of the pneumonia patients.

**METHODS**

**SAMPLE SOURCE, SCREENING AND CELL CULTURE ISOLATION**

Eight of 301 nasopharyngeal swab (NPS) specimens from hospitalized pneumonia patients (2017-18 at Sibu and Kapit Hospitals, Sarawak, Malaysia) were previously confirmed to contain CCoV using a semi-nested RT-PCR assay and Sanger sequencing (Tables 1 and S1)[17]. The eight pneumonia patients all came from Sibu Hospital (Table 1). Seven (87.5%) were less than five years in age, four were infants, and most were from Sarawak’s indigenous ethnic groups who typically live in rural/suburban longhouses or villages. Seven (87.5%) of the patients had evidence of a viral co-infection (Table 1). All bacterial blood cultures were negative, and all patients hospitalized for 4-6 days and recovered.

**RNA EXTRACTION AND RT-PCR**

RNA was extracted from suspended NPS samples using the 5X MagMAX Viral Isolation Kit (Applied Biosystems). Because one-step RT-PCR is less sensitive than nested/semi-nested RT-PCR, further characterization was conducted using one-step RT-PCR assays to ensure no contamination. Qiagen One-step RT-PCR kit was used with the indicated primers and cycling protocols (Table S2). Amplicons generated with CCoV-N-F/CCoV-N-R primers were gel-extracted using QIAquick® Gel Extraction Kit (Qiagen) and sequenced using Sanger method at the Molecular and Cellular Imaging Center (MCIC) at The Ohio State University (OSU), Ohio Agricultural Research and Development Center (Wooster, OH).
VIRUS ISOLATION IN A72 CELL CULTURE AND TRANSMISSION ELECTRON MICROSCOPY

Canine fibroblast tumor (A72) cells (received from Dr. Alfonso Torres, Cornell College of Veterinary Medicine) were maintained and used for sample inoculation as described previously [19]. Serially diluted NPS fluids (1:10-1:10,000) were used to inoculate the A72 monolayers. After 72 hours the infected cells and medium were harvested and used for RNA extraction with the RNEasy Mini Kit (Qiagen). The immune transmission electron microscopy (I-TEM) was conducted as described previously using polyclonal anti-canine coronavirus guinea pig serum (BEI Resources, NR-2727), the I-TEM images were captured at the MCIC [20].

COMPLETE GENOME SEQUENCING USING THE SANGER METHOD

The viral RNA was converted into cDNA using a SuperScript III cDNA synthesis kit (Invitrogen, USA).

Forty-two primer pairs (Table S3) covering the whole genome were designed based on the sequence of CCoV, strain TN-449, the most closely related strain as determined by BLASTn analysis of the partial N gene sequence of the newly identified CCoV for which the complete genome was available. Using these primers and Taq Platinum (Invitrogen) 12 amplicons (1.7-3.6 kb) were generated and purified using the QIAquick® Gel Extraction Kit and sequenced with 3× coverage using the Sanger dideoxy method with a BigDye Terminator version 3.1 cycle sequencing kit (Applied Biosystems, USA) at the MCIC and at the James Comprehensive Cancer Center Shared Genomics Core, The Ohio State University (Columbus, OH). After the initial analysis/sequence assembly, seven additional primer pairs were designed based on the newly generated sequences to close the remaining gaps (Table S3). The fragments were amplified and sequenced as described.
above. The 5’- and 3’-genomic ends were amplified using the 5’ and 3’ RACE System for Rapid Amplification of cDNA Ends (Invitrogen) according to the manufacturer’s manual.

SEQUENCE ASSEMBLY AND ANALYSIS

Raw sequences were trimmed to remove low-quality reads and amplicon-primer linkers. Each ORF was analyzed using Viral Genome ORF Reader (VIGOR) to predict viral protein sequences. The annotated CCoV genome was submitted to the GenBank (accession number is MW591993). The alignments were further analyzed Sequence Manipulation Suite (SMS, Version 2) (https://www.bioinformatics.org/sms2/) to determine nt identities between the reference and newly generated sequences. Sequence alignment and phylogenetic analysis were performed using the ClustalW method and the maximum-likelihood method with the general time reversible nucleotide substitution model and bootstrap tests of 1,000 replicates of MEGAX software. The CoV genomes for reference strains from GenBank used in the phylogenetic analyses are listed in (Table 3). The RIP (Recombinant Identification Program; http://www.hiv.lanl.gov/content/sequence/RIP/RIP.html) was used to identify recombination points within the CCoV-HuPn-2018 genome with the following parameters: window size of 400 and confidence threshold of 90%. Glycosylation prediction was conducted using the NetNGlyc 1.0 Server (http://www.cbs.dtu.dk/services/NetNGlyc/).

RESULTS

RT-PCR AND PARTIAL SEQUENCING OF CCoV

Samples from two of the eight patients from whom CCoV was earlier detected were positive in universal and CCoV-specific one-step RT-PCR assays (Table S2). This could be due to different quantity/integrity of CCoV in samples collected at variable time-points post infection. According to the BLASTn search, the sequences obtained for both samples using CCoV-N-F/CCoV-N-R primers
shared the highest nucleotide (nt) identity (96.31%) with several CCoV strains including TN-449 and HLJ-073 (listed in Table 3). We selected TN-449 sequence to design sequencing primers covering the complete genome (Table S3).

CCoV REPLICATION IN A72 CANINE CELLS

While eight CCoV-positive NPS samples were inoculated into A72 cells, only one sample (1153, Table 1) produced CPE in the cells (Figure S1). The A72 cell-passaged material (P1) was inoculated into A72 cells again and CPE was observed within the same timeframe (P2). RNA extracted from both P1 and P2 tested CCoV positive; RNA extracted from P1 was used for complete genome sequencing. This virus was visualized using I-TEM (Figure 1) and is referred to as CCoV-HuPn-2018 throughout (HuPn - human pneumonia).

GENOMIC ORGANIZATION OF CCoV-HuPn-2018

The assembled viral genome was 29,083/29,351 (due to differences between the two 7b forms) nt long excluding the poly(A) tail. The genomic organization and gene order were typical of that of other Alphacoronavirus 1 species: ORF1a1b, spike (S), ORF3a, ORF3b, ORF3c, envelope (E), membrane (M), nucleocapsid (N), ORF7a and ORF7b (Figure S2, Table 2). The structural and non-structural proteins (NSPs) were flanked by 5′- and 3′-untranslated regions with 3′–poly(A) tail.

The 5′-UTR consisted of 313 nt including the leader sequence (nt1–94) and the conserved core 5-CU(T)AAAC-3 (nt95–100) of the transcription regulatory sequence (TRS) that controls the mRNA synthesis during the subgenomic RNA discontinuous transcription. Similar TRS signals preceded five genes: S (nt 20,335), 3a (nt 24,787), E (nt 25,866); M (nt 26,156); N (nt 26,951); and 7a/b (nt 28,072) (Table 2). There were no TRS signals in front of 3b/3c and 7b suggesting that they may be expressed from polycistronic mRNAs. The 3′-end of the viral genome consists of a 275-nt 3′-UTR followed by the poly(A) tail.
Twenty thousand sixty-one nt following the 5’-UTR were occupied by the replicase gene encoding for two large polyproteins (pp), pp1a and pp1b, with pp1ab being synthesized through ribosomal slippage at position 12,339 as reported for highly related CCoV TN-449.

The SMS analysis demonstrated that the genome was mostly similar to CCoV strains TN-449, HLJ-073 and A76 and transmissible gastroenteritis virus (TGEV) Purdue strain sharing 93.31%, 91.744%, 90.63% and 91.47% nt identity, followed by feline CoV (FCoV)/feline infectious peritonitis virus (FIPV) strains (83.96-84.58% nt identity) (Table 3). This suggests CCoV-HuPn-2018 represents a novel strain within the Alpha-coronavirus 1 species.

Similar to the complete genome, CCoV-HuPn-2018 ORF1ab region shared the highest nt identity with that of TN-449 (95.84%), HLJ-073 (95.70%) and A76 (95.40%), followed by other CCoV (89-94·28%), various TGEV (92.6-94·49%) and FCoV (82.08-85.84%) strains.

Further, while the full-length S gene of CCoV-HuPn-2018 shared the highest nt identity with CCoV TN-449 (93.42%), its S1 domain was near identical to that of CCoV UCD-1 (for which only S1 sequence is available) sharing 99.19% nt identity, which was higher than for any other genomic region (Table 3). The S2 domain of CCoV-HuPn-2018 shared the highest identity of 97.13% with FCoV WSU 79-1683, providing additional evidence of recombinant (feline-canine, canine-TGEV) nature of most CCoV S genes.[21]

The remaining three genes encoding for structural proteins E, M and N shared the highest nt identity of 95.18%, 97.08% and 93.77%, respectively, with those of CCoV A76 (Table 3).

PHYLOGENETIC ANALYSIS

Phylogenetic analysis of complete genome sequences demonstrated that the novel CCoV-HuPn-2018 formed a monophyletic branch with CCoV, TGEV, FCoV strains and swine enteric CoV [TGEV with porcine epidemic diarrhea virus (PEDV) recombinant S gene].
Further, the full-length S gene of the CCoV-HuPn-2018 was closely related to CCoV strains and TGEV Purdue (Figure 2B), while its S1 and S2 domains were most closely related to CCoV UCD-1 and FCoV WSU 79-1683, respectively (Figure 2C and 2D).

Phylogenetic analysis of the E gene confirmed the close relatedness between CCoV-HuPn-2018 and CCoV A76; however, due to the high level of conservation of this gene, all of the analyzed Alphacoronavirus 1 strains with the exception of FIPV 79-1146 formed a tight cluster (Figure 2E). The M and N gene phylogenetic analysis confirmed that they were highly similar between CCoV-HuPn-2018 and CCoV A76, followed by other CCoVs and TGEV, while FCoVs formed separate clusters supporting higher degree of divergence in this genomic region evident from SMS analysis (Figure 2F and 2G; Table 3).
RECOMBINATION ANALYSIS

Potential recombination breakpoints between the background CCoV and TGEV strains were present throughout the ORF1ab, resulting in the short regions sharing more similarity with HLJ-073, A76 and TGEV Purdue strain (Figure 3A). Additionally, while the first two-thirds of the ORF1ab was relatively dissimilar between the CCoV-HuPn-2018 and FCoV WSU 79-1683/FIPV 79-1146, the similarity was higher (and comparable to CCoV/TGEV strains) in the last third with multiple recombination breakpoints (Figure 3A). The 3’-end of the genome downstream from the S gene was most similar between CCoV-HuPn-2018 and CCoV strain A76. While the S2 domain shared the highest similarity with that of FCoV WSU 79-1683, the sequence similarity between the CCoV-HuPn-2018 and all the background sequences in the hypervariable S1 region was low. Thus, this finding is consistent with the SMS and phylogenetic analysis results and indicates the recombinant nature of this strain (Figure 3A).

The S gene RIP analysis revealed the presence of the recombination point at ~2kb, with the S2 domain being highly similar to FCoV WSU 79-1683 as noted above (Figure 3B and 3C). The S1 domain RIP analysis allowed us to include the CCoV UCD-1 S1 domain into the analysis and confirm that it indeed shared the highest similarity with the CCoV-HuPn-2018 S1. These observations confirmed that the novel strain carries a recombinant CCoV/FCoV S protein.
STRUCTURAL/NON-STRUCTURAL PROTEIN ANALYSIS

The S protein was comprised of 1,448 aa similar to other CCoV II strains and shorter than S proteins of CCoV I characterized previously [22]. Twenty-nine potential glycosylation sites were predicted in the S protein of the newly identified CCoV-HuPn-2018 (Figure S3A) similar to other CCoVs [22]. Unlike CCoV I, some FCoV and all beta- and gammacoronaviruses, the characteristic multibasic motif (RRXRR) – furin recognition site was absent in the S protein of CCoV-HuPn-2018, suggesting that the virus carries an uncleaved S protein, similar to most other alphacoronaviruses [15]. Thus, this novel strain shares more similarities with CCoV-II strains.

Surprisingly, there were no unique deletions or insertions in the S protein of CCoV-HuPn-2018. Also, there were a total of 5 aa differences between the CCoV-HuPn-2018 and CCoV UCD-1 in the S1 domain; however, these aa were identical to those found in the TGEV Purdue S1 and not unique.

The E protein was 81-aa long and did not contain any N-glycosylation sites, whereas three N-glycosylated residues have been predicted in each the 261-aa long M and the 370-aa long N proteins (Figures S3B and S3C), which is similar to several other FCoV/CCoV strains. While no evidence of recombination was observed for E, M or N proteins, the N protein contained a unique 12-aa deletion within the SR-rich region (located between aa 164 and 177 for other CCoV strains). Presence of this deletion was confirmed in the original NSP samples 1116 and 1153.

The three ORFs 3a, 3b and 3c between S and E genes encoded for proteins with sizes of 71, 71 and 244 aa, respectively. ORF3, previously found in CCoV I genomes only [14, 22], was not present in the new strain. The 3’-end accessory protein gene 7a encoded for 101-aa, while there were at least 2 forms of 7b: full-length (213-aa) and the one with a 227-nt deletion (leading to a frame shift and premature truncation of the putative protein).

DISCUSSION
Our previous study identified eight pneumonia patients with molecular evidence of CCoV in their 
NPS specimens [17]. Partial sequencing and BLASTn analysis suggested that these were closely related 
but distinct CCoV variants (Table S1). The eight pneumonia patients were mainly children living in long 
houses or villages in rural/suburban areas where domestic animal and jungle wildlife exposure with the 
family is common.

Here, we confirmed the presence of CCoV with different, less sensitive, one-step RT-PCR assays in 
two specimens, grew a virus in A72 cells from one specimen, and conducted a complete genome 
sequence analysis of the CCoV. Our results demonstrated that CCoV-HuPn-2018 is a novel canine-feline-
like recombinant strain with a unique N. To our knowledge, this is the first report suggesting that a CCoV 
without major genomic re-arrangements or adaptive modifications in the S protein might replicate in 
association with pneumonia in a human host.

The conducted analyses demonstrated that the newly identified CCoV-HuPn-2018 was most closely 
related to CCoV TN-449, while its S1 and S2 domains shared the highest nt identity with that of CCoV 
UCD-1 and FCoV WSU 79-1683, respectively. These findings are suggestive of the recombinant nature 
of this strain, similar to many previously characterized CCoVs [21]. Phylogenetic and recombinational 
analyses confirmed that CCoV-HuPn-2018 was only distantly related to other alphacoronavirus species 
including HCoVs (229E and NL63) and bat CoVs and likely originated via multiple recombination events 
between different Alphacoronavirus 1 strains, but not other alphacoronaviruses.

The ability of the novel strain to replicate in A72 canine cells, the absence of ORF3, the higher 
overall similarity with CCoV-II strains (TN-449 and HLJ-073) and the lack of the furin cleavage site 
between S1 and S2 domains suggest that it belongs to CCoV genotype II [22].

The unique feature not found in any other known CCoVs and Alphacoronavirus 1 species, namely the 
12-aa deletion in the middle portion of the N protein was confirmed in both original NSP samples 1153 
and 1116. While insertions/deletions in the N protein are not found among the known Alphacoronavirus 1
strains, the deletion of the SR-rich domain within the middle region of SARS-CoV N protein reportedly resulted in dramatic changes in its cellular localization soon after its zoonotic transmission [23]. Thus, similar to SARS-CoV, CCoV-HuPn-2018 possesses some unique genetic features suggestive of recent zoonotic transmission. Notably, such N protein re-arrangements are characteristic for SARS-CoV/SARS-CoV-2 with higher case-fatality rates [24].

While SARS-CoV and FCoV NSP7b was not essential for viral replication in vitro and in vivo experiments, its deletion/truncation may be associated with attenuated phenotype [25]. Disruption in the expression of the NSPs following zoonotic transmission of SARS-CoV was reported previously suggesting it may represent an adaptive mechanism [26]. Finally, deletions unique to FIPVs were found in ORFs 3c and/or 7b that were hypothesized to be responsible to the shift from enteric (FCoV) to FIPV phenotype and increased pathogenicity [27].

The ability of CCoV to quickly evolve via frequent recombination events and induce disease of variable severity is even more concerning given these data indicating that circulating CCoV may already be transmittable to humans.

This study had a number of limitations. First, we have not met recognized standards of causality such as Koch’s postulates or Bradford Hill criteria. Second, we recognize that the detected CCoVs could only be “carried” in some of the eight patients’ airways not causing disease. However, identification of: 1) FCoV-like CoVs in influenza-negative patients with acute respiratory symptoms in Arkansas and 2) porcine deltacoronavirus in children in Haiti further emphasizes that Alphacoronavirus 1 species may be infectious/pathogenic to humans [18, 28].

In conclusion, we recovered and characterized a novel recombinant coronavirus, CCoV-HuPn-2018, from a hospitalized pneumonia patient. While possessing some unique characteristics likely suggestive of a recent zoonotic transmission, this novel strain with recombinant CCoV UCD-1/FCoV WSU 79-1683 S protein shares multiple genomic features of wide-spread CCoV-II. Further studies to investigate CCoV
prevalence, seroprevalence and pathogenic potential in humans are needed. Additional studies should be conducted to evaluate the biological relevance of the observed deletion in the N protein.
NOTES

AUTHOR CONTRIBUTIONS

ANV – designed, overseen and provided financial support for the experiments on CCoV-HuPn-2018 characterization and sequences, sequenced parts of the genome, analyzed the data and wrote the manuscript; AD – conducted most of the experiments on CCoV-HuPn-2018 cell culture isolation and Sanger sequencing; DD – conducted some of the experiments on Sanger sequencing; LX – screened 301 samples and identified the eight samples positive for CoV/CCoV; THT – coordinated sample collection, obtaining ethical clearance, collection and processing of the patient demographic data; JSYL – coordinated sample collection, obtaining ethical clearance, collection and processing of the patient demographic data; LJS – critically revised the manuscript draft; GCG – led the original studies, oversaw this new study, provided financial support and revised the manuscript.

ACKNOWLEDGMENTS

We thank King-Ching Hii, Jane K. Fieldhouse, Jakie Ting, Antoinette Berita, Tham Thi Nguyen, See-Chang Wong, Toh-Mee Wong, Wei-Honn Lim, Siaw-Jing Ha, Chuet-Zou Lau, Sing-Ling Kong, Emily S. Bailey, Mohd Raili Suhailei, Kristen K. Coleman, Son Thê Than, Tyler E. Warkentien, Patrick J. Blair, Nga-Hung Ngu, Khai-Fatt Chao, Cheng-Ing Kong, Zhen-Hao Chin, Edmund Kwang-Yuen Wong, Tiana Ti, Hilary Hon-Yun Kueh, Cornelius Jambol, Goh Hieng-Hua Goh, and Velarie Bill, Tiing-Tiing Chua, Raquel A. Binder, Raquel A. Natalie A. Alarja, Emily R. Robie, Anfal Abdelgadir, and John A. Lednicky for their clinical, laboratory, scientific, and administrative contributions to this work. This research was conducted in partnership with Duke University, the Duke Global Health Institute, Sibu Hospital Clinical Research Center, SEGi University Sibu Clinical Campus, and Ohio State University. We also thank Tea Meulia (Molecular and Cellular Imaging Center of the Ohio Agricultural Research and Development Center) for assistance with transmission electron microscopy. The study – source of NSP samples – has received a scientific review, and all procedures followed were in accordance with the
ethical standards of the Malaysian Ministry of Health’s Medical Research and Ethics Committee (protocol number NMRR-17-316-34395), the Duke University Health System Institutional Review Board, DukeNUS Medical School Ethical Review Board, and the Naval Medical Research Center-Asia Human Research Protection Program (HRPO no. W911QY-16-D-0058).

**FUNDING**

This work was supported by the US Naval Medical Research Center-Asia and Vysnova Partners [grant numbers SC-2016-SABER-003-002, SC-2017- SABER-010-001] to GG, Professor Gregory Gray’s discretionary funds from Duke University’s Global Health Institute and Dr. Vlasova startup funds from The Ohio State University.

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.
REFERENCES

1. van der Hoek L. Human coronaviruses: what do they cause? Antiviral therapy 2007; 12(4 Pt B): 651-8.

2. Tyrrell DA, Bynoe ML. Cultivation of a Novel Type of Common-Cold Virus in Organ Cultures. British medical journal 1965; 1(5448): 1467-70.

3. Hamre D, Procknow JJ. A new virus isolated from the human respiratory tract. Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine 1966; 121(1): 190-3.

4. Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361(9366): 1319-25.

5. Memish ZA, Mishra N, Olival KJ, et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerging infectious diseases 2013; 19(11): 1819-23.

6. Hu B, Ge X, Wang LF, Shi Z. Bat origin of human coronaviruses. Virology journal 2015; 12: 221.

7. Ciotti M, Angeletti S, Minieri M, et al. COVID-19 Outbreak: An Overview. Chemotherapy 2019; 64(5-6): 215-23.

8. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nature medicine 2020; 26(4): 450-2.

9. Wang LF, Eaton BT. Bats, civets and the emergence of SARS. Current topics in microbiology and immunology 2007; 315: 325-44.

10. Li H, Mendelsohn E, Zong C, et al. Human-animal interactions and bat coronavirus spillover potential among rural residents in Southern China. Biosafety and health 2019; 1(2): 84-90.
11. Decaro N, Buonavoglia C. Canine coronavirus: not only an enteric pathogen. The Veterinary clinics of North America Small animal practice 2011; 41(6): 1121-32.

12. Pratelli A, Martella V, Decaro N, et al. Genetic diversity of a canine coronavirus detected in pups with diarrhoea in Italy. Journal of virological methods 2003; 110(1): 9-17.

13. Pratelli A, Martella V, Pistello M, et al. Identification of coronaviruses in dogs that segregate separately from the canine coronavirus genotype. Journal of virological methods 2003; 107(2): 213-22.

14. Lorusso A, Decaro N, Schellen P, et al. Gain, preservation, and loss of a group 1a coronavirus accessory glycoprotein. Journal of virology 2008; 82(20): 10312-7.

15. de Haan CA, Haijema BJ, Schellen P, et al. Cleavage of group 1 coronavirus spike proteins: how furin cleavage is traded off against heparan sulfate binding upon cell culture adaptation. Journal of virology 2008; 82(12): 6078-83.

16. Li W, Hulswit RJG, Kenney SP, et al. Broad receptor engagement of an emerging global coronavirus may potentiate its diverse cross-species transmissibility. Proceedings of the National Academy of Sciences of the United States of America 2018; 115(22): E5135-E43.

17. Xiu L, Binder RA, Alarja NA, et al. A RT-PCR assay for the detection of coronaviruses from four genera. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2020; 128: 104391.

18. Silva CS, Mullis LB, Pereira O, Jr., et al. Human Respiratory Coronavirus Detected In Patients with Influenza-Like Illness in Arkansas, USA. Virology & mycology : infectious diseases 2014; 2014(Suppl 2).
19. Amici C, Di Caro A, Ciucci A, et al. Indomethacin has a potent antiviral activity against SARS coronavirus. Antiviral therapy 2006; 11(8): 1021-30.

20. Hasoksuz M, Alekseev K, Vlasova A, et al. Biologic, antigenic, and full-length genomic characterization of a bovine-like coronavirus isolated from a giraffe. Journal of virology 2007; 81(10): 4981-90.

21. Licitra BN, Duhamel GE, Whittaker GR. Canine enteric coronaviruses: emerging viral pathogens with distinct recombinant spike proteins. Viruses 2014; 6(8): 3363-76.

22. Decaro N, Mari V, Elia G, et al. Full-length genome analysis of canine coronavirus type I. Virus research 2015; 210: 100-5.

23. He R, Dobie F, Ballantine M, et al. Analysis of multimerization of the SARS coronavirus nucleocapsid protein. Biochemical and biophysical research communications 2004; 316(2): 476-83.

24. Gussow AB, Auslander N, Faure G, Wolf YI, Zhang F, Koonin EV. Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses. Proceedings of the National Academy of Sciences of the United States of America 2020; 117(26): 15193-9.

25. Liu DX, Fung TS, Chong KK, Shukla A, Hilgenfeld R. Accessory proteins of SARS-CoV and other coronaviruses. Antiviral research 2014; 109: 97-109.

26. Oostra M, de Haan CA, Rottier PJ. The 29-nucleotide deletion present in human but not in animal severe acute respiratory syndrome coronaviruses disrupts the functional expression of open reading frame 8. Journal of virology 2007; 81(24): 13876-88.

27. Vennema H, Poland A, Foley J, Pedersen NC. Feline infectious peritonitis viruses arise by mutation from endemic feline enteric coronaviruses. Virology 1998; 243(1): 150-7.
28. Lednicky JA, Tagliamonte MS, White SK, et al. Emergence of porcine delta-coronavirus pathogenic infections among children in Haiti through independent zoonoses and convergent evolution. medRxiv : the preprint server for health sciences 2021.

29. Fieldhouse JK, Bailey ES, Toh TH, et al. Panspecies molecular assays detect viral pathogens missed by real-time PCR/reverse-transcriptase PCR among pneumonia patients, Sarawak, Malaysia. Tropical diseases, travel medicine and vaccines 2020; 6: 13.

30. Fieldhouse JK, Toh TH, Lim WH, et al. Surveillance for respiratory syncytial virus and parainfluenza virus among patients hospitalized with pneumonia in Sarawak, Malaysia. PloS one 2018; 13(8): e0202147.

31. Toh TH, Hii KC, Fieldhouse JK, et al. High Prevalence of Viral Infections Among Hospitalized Pneumonia Patients in Equatorial Sarawak, Malaysia. Open forum infectious diseases 2019; 6(3): ofz074.
Table 1. Demographic and clinical characteristics of the eight patients with molecular evidence of canine coronavirus in their nasopharyngeal swab specimen.

| ID | Gender / Age/Ethnicity | Town / Housing Type (Number of cohabitants at home) | Underlying condition / medication | Known exposure to animals | Highest oxygen support during admission | Duration of hospital stay (complete days) | Other concomitant pathogens detected* |
|----|------------------------|----------------------------------------------------|----------------------------------|---------------------------|----------------------------------------|-----------------------------------------|-------------------------------------|
| 1  | Male /13½ months / Iban | Sibu/unknown (2)                                  | Pre-school wheeze / inhaled Budesonide | No                        | No information                         | No information                        | Adenovirus                          |
| 1  | Male/9½ months / Iban    | Sibu/longhouse (9)                                | Glucose-6-phosphate dehydrogenase deficiency/oral amoxycillin | No                        | Nasal prong oxygen 1L/min              | 5                                       | Adenovirus                          |
| 1  | Female/2½ years/ Iban    | Bintulu/longhouse (9)                             | None                             | No                        | No information                         | No information                        | Parainfluenza virus 3               |
| 1  | Female/11 months / Iban  | Sibu/longhouse (7)                                | None                             | Cats                      | Nasal prong oxygen 1L/min              | 5                                       | Parainfluenza virus 3               |
| 1  | Female/4½ years/ Chinese | Sibu/townhouse (4)                               | None                             | Cats and dogs             | No information                         | No information                        | Influenza A                         |
| 1  | Male/5½ months/ Melana u | Daro/village (10)                                | None/oral ampicillin and cloxacillin | No                        | No information                         | No information                        | Rhinovirus C                        |
| 1  | Female/10 months / Bidayuh | Julau/longhouse (4)                             | Pre-school wheeze/inhaled fluticasone | No                        | Nasal prong oxygen 1L/min              | 6                                       | Adenovirus                          |
| 2  | Female/37½ years/ Iban   | Sibu/staff quarter (15)                          | Bronchial asthma/inhaled Fluticasone | Dogs                      | Nasal prong oxygen 3L/min              | 4                                       | None                                |

CCoV-HuPn-2018 was isolated from sample 1153, bolded. *The patients’ nasopharyngeal swabs were studied with molecular assays for adenovirus, human enterovirus, influenza A, B, C, and D, respiratory syncytial virus A and B, parainfluenza viruses 1, 2, 3 and 4, and rhinovirus [29-31].
Table 2. Complete genome and individual gene length and other characteristics of CCoV-HuPn-2018

| Genomic region/ORF number | Coding sequence | Length, nt | Putative TRS start nt/sequence | Protein name | Protein size, aa | Note |
|---------------------------|-----------------|------------|-------------------------------|--------------|-----------------|------|
| 5'-UTR                    | N/A             | 313        | N/A                           | N/A          | N/A             | Similar to other CCoVs |
| 3'-UTR                    | N/A             | 275        | N/A                           | N/A          | N/A             | |
| ORF1/b                    | 314-20,374      | 20,061     | 90                            | TCGAACTAAACGAAAT | Pp1ab         | 6,686 |
|                           |                 |            |                               |              |                 | Putative ribosomal slippage is at position 12,339 |
| ORF2                      | 20,371-24,717   | 4,347      | 20,335                        | GTTACTAAACTTTG | S              | 1,448 |
|                           |                 |            |                               |              |                 | Recombinant structure with the S1 domain most closely related to CCoV UCD-1 and the S2 domain most closely related to FCoV WSU 79-1683 |
| ORF3a                     | 24,820-25,035   | 216        | 24,787                        | AGAACTAAACTTATG | 3a             | 71 |
|                           |                 |            |                               |              |                 | Only one TRS before 3a was found; so 3a, 3b and 3c are likely to be expressed from polycistronic mRNAs |
| ORF3b                     | 24,980-25,195   | 216        | N/A                           | N/A          | 3b              | 71 |
| ORF3c                     | 25,192-25,926   | 735        | N/A                           | N/A          | 3c              | 244 |
| ORF4                      | 25,913-26,158   | 246        | 25,866                        | GGTTCTAAACGAAAT | E              | 81 |
|                           |                 |            |                               |              |                 | No unique features |
| ORF5                      | 26,169-26,954   | 786        | 26,156                        | TGAACTAAACAAAT | M              | 261 |
| ORF6                      | 26,967-28,079   | 1,113      | 26,951                        | ATAACTAAACTTCTA | N             | 370 |
|                           |                 |            |                               |              |                 | Contains 36 nt deletion in the middle region |
| ORF7a                     | 28,084-28,389   | 306        | 28,072                        | CGAACTAAACGAATG | 7a             | 101 |
|                           |                 |            |                               |              |                 | Only one TRS before 7a is located; 7b is being expressed from polycistronic mRNAs |
| ORF7b*                    | 28,394-28,808/29,035 | 415/642 | N/A                           | N/A          | 7b              | 34/213 |
|                           |                 |            |                               |              |                 | *Truncated, likely non-functional, contains an out of frame 227-nt deletion close to its 5’ end followed by premature stop codons, and full-length forms. |
Table 3. Percent (%) identities of CCoV-HuPn-2018 to Alphacoronavirus-1 reference strains in the complete genomic sequence and genes for structural proteins.

| Alphacoronavirus 1 | Strain       | Accession number | Nt Identity (%) to CCoV-HuPn-2018 |
|-------------------|--------------|------------------|-----------------------------------|
|                   |              |                  | Complete genome | S       | S1   | S2   | E     | M     | N     |
| CCoV-IIa          | TN-449       | JQ404410.1       | 93.31%*          | 93.42%  | 73.22% | 95.20% | 93.57% | 95.08% | 93.42% |
| CCoV-IIa          | HLJ-073      | KY063618.2       | 91.74%           | 93.33%  | 73.32% | 95.20% | 93.17% | 95.08% | 93.33% |
| CCoV-IIc          | A76          | JN856008.2       | 90.63%           | 93.77%  | 53.80% | 85.42% | 95.18% | 97.08% | 93.77% |
| CCoV              | UCD-1        | AF116248.1       | N/A               | N/A     | 99.19% | N/A   | N/A   | N/A   | N/A   |
| TGEV              | Purdue (virulent) | DQ811789.2     | 91.47%           | 92.12%  | 90.93% | 94.59% | 93.98% | 92.65% | 92.12% |
| FCoV-II           | WSU-79-1683  | JN634064.1       | 84.58%           | 74.91%  | 72.80% | 97.13% | 93.68% | 86.25% | 74.91% |
| FCoV-II/FIPV      | 79-1146      | DQ010921.1       | 84.04%           | 75.5%   | 73.04% | 95.04% | 79.92% | 81.77% | 75.5% |

* Blue shading indicates the highest nt identity between CCoV-HuPn-2018 and a given strain.
FIGURE LEGENDS

**Figure 1.** Immune transmission electron microscopy image of CCoV-HuPn-2018 from an A72 cell culture. The sample was incubated with anti-canine coronavirus guinea pig serum, leading to the specific viral-antibody aggregates. The bar represents 100 nm.

**Figure 2.** Phylogenetic tree based on complete genome (A), S gene (B), S1 (C), S2 domain (D), E gene (E), M gene (F) and N gene (G) sequences of the CCoV-HuPn-2018 viral isolate and other alphacoronavirus species. Bootstrap values are represented at key nodes. Scale bar indicates nucleotide substitutions per site. CCoV, canine coronavirus; TGEV, transmissible gastroenteritis virus; FCoV, feline coronavirus; FIPV, feline infectious peritonitis virus; HCoV, human coronavirus; SADS-CoV, swine acute diarrhea syndrome coronavirus; BtCoV, bat coronavirus; PEDV, porcine epidemic diarrhea virus. The evolutionary history was inferred by using the Maximum Likelihood method and General Time Reversible model. This analysis involved 13 nucleotide sequences. Evolutionary analyses were conducted in MEGA X. The newly identified viral isolate CCoV-HuPn-2018 labeled with black circle marker.

**Figure 3.** Recombinational analysis of the CCoV-HuPn-2018 complete genome (A), S1 (B) and S2 (C) domains. At each position of the window, the query sequence CCoV-HuPn-2018 was compared with background sequences for six strains shown in the legend on the right. The x-axis represents the length of the genome, and the y-axis represents the similarity value. When the query sequence is similar to the background sequence(s), the homologous regions are indicated as thick dashed lines (of the corresponding color) on the top of the plot. Arrows represent potential recombination breakpoints.
Figure 2

A

B

C

D

E

F

G

Downloaded from https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab456/6278597 by guest on 28 May 2021
Figure 3